Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2011 1
2012 2
2013 1
2014 2
2016 2
2017 3
2018 1
2019 2
2020 2
2021 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
My Vocational Situation (MVS): Case Example and Psychometric Review.
Nitsch KP, Pedersen J, Miliotto A, Petersen B, Robbins S, Garcia A, Hoisington MA, The KJ, Smiley J, Janikowski T. Nitsch KP, et al. Among authors: miliotto a. Am J Occup Ther. 2017 Mar/Apr;71(2):7102405010p1-7102405010p4. doi: 10.5014/ajot.2017.025288. Am J Occup Ther. 2017. PMID: 28218601 Review.
A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer.
McGray AJR, Eppolito C, Miliotto A, Singel KL, Stephenson K, Lugade A, Segal BH, Keler T, Webster G, Lichty B, Kozbor D, Odunsi K. McGray AJR, et al. Among authors: miliotto a. Cancer Immunol Immunother. 2021 Dec;70(12):3451-3460. doi: 10.1007/s00262-021-02936-1. Epub 2021 Apr 20. Cancer Immunol Immunother. 2021. PMID: 33880648 Free PMC article.
NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer.
Szender JB, Papanicolau-Sengos A, Eng KH, Miliotto AJ, Lugade AA, Gnjatic S, Matsuzaki J, Morrison CD, Odunsi K. Szender JB, et al. Among authors: miliotto aj. Gynecol Oncol. 2017 Jun;145(3):420-425. doi: 10.1016/j.ygyno.2017.03.509. Epub 2017 Apr 6. Gynecol Oncol. 2017. PMID: 28392127 Free PMC article.
Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer.
Liu S, Matsuzaki J, Wei L, Tsuji T, Battaglia S, Hu Q, Cortes E, Wong L, Yan L, Long M, Miliotto A, Bateman NW, Lele SB, Chodon T, Koya RC, Yao S, Zhu Q, Conrads TP, Wang J, Maxwell GL, Lugade AA, Odunsi K. Liu S, et al. Among authors: miliotto a. J Immunother Cancer. 2019 Jun 20;7(1):156. doi: 10.1186/s40425-019-0629-6. J Immunother Cancer. 2019. PMID: 31221207 Free PMC article.
Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.
Odunsi K, Matsuzaki J, James SR, Mhawech-Fauceglia P, Tsuji T, Miller A, Zhang W, Akers SN, Griffiths EA, Miliotto A, Beck A, Batt CA, Ritter G, Lele S, Gnjatic S, Karpf AR. Odunsi K, et al. Among authors: miliotto a. Cancer Immunol Res. 2014 Jan;2(1):37-49. doi: 10.1158/2326-6066.CIR-13-0126. Cancer Immunol Res. 2014. PMID: 24535937 Free PMC article. Clinical Trial.
Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer.
Tsuji T, Eng KH, Matsuzaki J, Battaglia S, Szender JB, Miliotto A, Gnjatic S, Bshara W, Morrison CD, Lele S, Emerson RO, Wang J, Liu S, Robins H, Lugade AA, Odunsi K. Tsuji T, et al. Among authors: miliotto a. Oncotarget. 2020 Jul 7;11(27):2669-2683. doi: 10.18632/oncotarget.27666. eCollection 2020 Jul 7. Oncotarget. 2020. PMID: 32676168 Free PMC article.
19 results